BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
J.T. Jørgensen, K.B. Nielsen. Comprehensive Medicinal Chemistry III2017; : 530 doi: 10.1016/B978-0-12-409547-2.12336-4
2
Felice Pasini, Anna Paola Fraccon, Yasmina Modena, Maria Bencivenga, Simone Giacopuzzi, Francesca La Russa, Milena Gusella, Giovanni de Manzoni. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Gastric Cancer 2017; 20(1): 31 doi: 10.1007/s10120-016-0626-0
3
Sofie L. Nielsen, Søren Nielsen, Mogens Vyberg. Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction AdenocarcinomasApplied Immunohistochemistry & Molecular Morphology 2017; 25(5): 320 doi: 10.1097/PAI.0000000000000463
4
Hung-Man Yu, Jyun-Hong Chen, Kun-Liang Lin, Wuu-Jyh Lin. Synthesis of68Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imagingJournal of Labelled Compounds and Radiopharmaceuticals 2015; 58(7): 299 doi: 10.1002/jlcr.3296
5
Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto. Updated evidence on adjuvant treatments for gastric cancerExpert Review of Gastroenterology & Hepatology 2015; 9(12): 1549 doi: 10.1586/17474124.2015.1094373
6
Federico Coccolini, Giulia Montori, Marco Ceresoli, Simona Cima, Maria Carla Valli, Gabriela E Nita, Arianna Heyer, Fausto Catena, Luca Ansaloni. Advanced gastric cancer: What we know and what we still have to learnWorld Journal of Gastroenterology 2016; 22(3): 1139-1159 doi: 10.3748/wjg.v22.i3.1139
7
Gaetano Romano. Tumor markers currently utilized in cancer careMaterials and Methods 2015; 5 doi: 10.13070/mm.en.5.1456
8
Tasuku Matsuoka, Masakazu Yashiro. Recent advances in the HER2 targeted therapy of gastric cancerWorld Journal of Clinical Cases 2015; 3(1): 42-51 doi: 10.12998/wjcc.v3.i1.42
9
Andrew S. Dixon, Sun Jin Kim, Brett K. Baumgartner, Sylvia Krippner, Shawn C. Owen. A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous ImmunoassaysScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-07569-y
10
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors2017; : 243 doi: 10.1016/B978-0-12-809400-6.00011-1
11
Alexandra Thiel, Ari Ristimäki. Targeted therapy in gastric cancerAPMIS 2015; 123(5): 365 doi: 10.1111/apm.12359
12
G Jomrich, SF Schoppmann. Targeting HER 2 and angiogenesis in gastric cancerExpert Review of Anticancer Therapy 2016; 16(1): 111 doi: 10.1586/14737140.2016.1121110
13
Mayuko Saito, Kentaro Yamashita, Yoshiaki Arimura, Hiroyuki Kaneto, Hiroyuki Okuda, Masanori Nojima, Takeshi Hagiwara, Kazuya Suzuki, Takeya Adachi, Akira Goto, Kohei Nakachi, Atsushi Yawata, Mitsuru Yoshimoto, Tokuma Tanuma, Yasushi Adachi, Satoshi Yamaoka, Tsunenori Mizukoshi, Mariko Kawayama, Yasuo Hamamoto, Yasuhisa Shinomura. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)Acta Oncologica 2016; 55(3): 309 doi: 10.3109/0284186X.2015.1107189
14
Robert Roskoski. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitorsPharmacological Research 2014; 87: 42 doi: 10.1016/j.phrs.2014.06.001
15
MIAOLIN ZHU, XIAOYUAN YAO, MIN WU, HAI QIAN, YAN WU, YONGCHANG CHEN. Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cellsMolecular Medicine Reports 2016; 13(2): 1909 doi: 10.3892/mmr.2015.4688